|Application ||WB, IHC-P|
|Calculated MW||25206 Da|
|Dilution||IHC-P (5 µg/ml), WB (1:500 - 1:2000),|
|Other Names||PRG2, BMPG, Bone marrow proteoglycan, Bone-marrow proteoglycan, Eosinophil major basic protein, MBP1, Natural killer cell activator, Proteoglycan 2, Proteoglycan 2 preproprotein|
|Target/Specificity||Human PRG2 / Proteoglycan 2|
|Reconstitution & Storage||PBS, pH 7.3, 0.02% sodium azide, 50% glycerol. Long term: -80°C; Short term: -20°C. Avoid freeze-thaw cycles.|
|Precautions||PRG2 / Proteoglycan 2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.|
|Cellular Location||Bone marrow proteoglycan: Secreted. Note=The proform is secreted|
|Tissue Location||High levels of the proform in placenta and pregnancy serum; in placenta, localized to X cells of septa and anchoring villi. Lower levels in a variety of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow and colon.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.
Barker R.L.,et al.J. Exp. Med. 168:1493-1498(1988).
Barker R.L.,et al.Submitted (OCT-1989) to the EMBL/GenBank/DDBJ databases.
Barker R.L.,et al.Gene 86:285-289(1990).
McGrogan M.,et al.J. Exp. Med. 168:2295-2308(1988).
Yoshimatsu K.,et al.Mol. Immunol. 29:537-546(1992).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.